Scientific researchers around the country are concerned after the National Institutes of Health canceled meetings this week with very little explanation. The move comes after federal health officials were told to halt public communications until they could be reviewed by a Trump appointee.

President Trump has imposed temporary freezes at the National Institutes of Health on meetings, travel, communications and hiring, citing the need to review protocols.

The FDA is the leading science-based consumer protection agency in the world. Three former senior officials write about what they hope the Trump administration doesn’t change.

The U.S. Department of Health and Human Services has paused public communications until Feb. 1 as Trump appointees take control of health agencies.

Robert F. Kennedy Jr. has big plans for the FDA if he's confirmed as Secretary of Health and Human Services. FDA Commissioner Robert Califf explains why certain changes may not be that easy — or desirable.

President Trump ordered a pause on communications from several federal health organizations, including the FDA, the CDC, and the National Institutes of Health.

The Trump administration’s freeze on communications from U.S. health agencies is leading to another disruption: the abrupt cancellation of scientific meetings. The move covers a swath of health conditions,

Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external communications, such as regular scientific reports, updates to websites and health advisories,

The agencies are charged with making decisions that touch the lives of every American and are the source of crucial information to health-care providers.

Dr. Dorothy Fink, the acting secretary for the Department of Health and Human Services under President Donald Trump, has instructed the heads of every federal health agency to stop public communication.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

The director of the National Institutes of Health, Dr. Monica Bertagnolli, announced that she will step down Friday, 14 months after she took the position on Nov. 9, 2023.